Goals of therapy and guidelines for treatment success in symptomatic gastroesophageal reflux disease patients.
about
Symptoms of gastroesophageal reflux disease in severely mentally retarded people: a systematic review.Lifestyle factors affecting gastroesophageal reflux disease symptoms: a cross-sectional study of healthy 19864 adults using FSSG scores.Protonated form: the potent form of potassium-competitive acid blockersMultimodal pain stimulations in patients with grade B oesophagitisManagement strategies for gastroesophageal reflux disease.Experimental human pain models in gastro-esophageal reflux disease and unexplained chest painOn-demand therapy for gastroesophageal reflux disease.Dexlansoprazole MR: a review.Pain in cognitively impaired children: a focus for general pediatricians.Development and validation of a patient-reported outcome instrument in partial responders to proton pump inhibitors.Randomised clinical trial: sodium alginate oral suspension is non-inferior to omeprazole in the treatment of patients with non-erosive gastroesophageal disease.Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom ReseFactors affecting response to proton pump inhibitor therapy in patients with gastroesophageal reflux disease: a multicenter prospective observational study.Development and validation of a simple and multifaceted instrument, GERD-TEST, for the clinical evaluation of gastroesophageal reflux and dyspeptic symptomsCorrelation between symptomatic improvement and quality of life in patients with reflux and dyspeptic symptoms.Long-term outcome of endoluminal gastroplication in the treatment of gastro-oesophageal reflux disease: effect of a second procedure.Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal and intragastric pH in patients with gastroesophageal reflux disease (GERD).Impact of Comorbid Irritable Bowel Syndrome on Treatment Outcome in Non-Erosive Reflux Disease on Long-Term Proton Pump Inhibitor in Japan.Patients' subjective symptoms, quality of life and intake of food during the recovery period 3 and 12 months after upper gastrointestinal surgery.
P2860
Q33343080-9A7FF683-B0EC-4D0E-90FE-C2467C7E3441Q34254969-5F8E88C2-5B4F-43EE-AB9F-B020AE84B45EQ35171617-E19EA335-D1E7-413F-81DA-EB1E586A4672Q35760744-56197376-992A-4F32-A264-F4B3662B3471Q35868522-EEACD554-B772-4E65-8679-C29C1893F328Q36485768-8E7EA128-C7EA-4AC0-A736-441DA14E5F64Q36677627-3E3AD457-8CC3-4D0F-875E-DF3BE07893D2Q37848846-0087F3C4-3C71-491D-BA6B-2BEB05E0E4E4Q37994604-FB501F33-B142-4E41-ACBA-3C06F175B050Q38447198-7FF370DF-983D-4D5D-9EC6-15D0A24BAC17Q39220802-07C28698-5535-440D-90DF-5717C44E6718Q39260588-650447A3-82DD-4E71-9ACE-150724F8798BQ41103071-66B5D962-C0CC-499A-880C-799D2E494B01Q41191117-CDDE2B3E-E2F1-47FA-993D-199551920A3BQ42132392-34C8C21A-74E2-4FC1-9C55-DE4596B09604Q44109024-6F877365-7598-4251-94F3-E2F00B53442EQ46869941-4E14CD21-2565-406F-ACE1-2AB3162179DAQ47847807-E0276167-B3FE-4847-A723-2CB009E6BBDBQ48480183-F9BF07E6-FD89-4031-BA54-361AF9708004
P2860
Goals of therapy and guidelines for treatment success in symptomatic gastroesophageal reflux disease patients.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Goals of therapy and guideline ...... ageal reflux disease patients.
@ast
Goals of therapy and guideline ...... ageal reflux disease patients.
@en
type
label
Goals of therapy and guideline ...... ageal reflux disease patients.
@ast
Goals of therapy and guideline ...... ageal reflux disease patients.
@en
prefLabel
Goals of therapy and guideline ...... ageal reflux disease patients.
@ast
Goals of therapy and guideline ...... ageal reflux disease patients.
@en
P1476
Goals of therapy and guideline ...... ageal reflux disease patients.
@en
P2093
Peter Bytzer
P356
10.1016/S0002-9270(03)00013-3
P407
P433
P577
2003-03-01T00:00:00Z